Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669073 | 0.92 | GCK (0.59) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL1426924 | 0.89 | GCK (0.60) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL12781684 | 0.89 | GCK (0.60) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL1041338 | 0.88 | GCK (0.61) | GCKKCNH2 | |
| SCHEMBL1043189 | 0.84 | GCK (0.53) | GCKRARG | |
| SCHEMBL1042657 | 0.81 | GCK (0.64) | GCKKCNH2RARG | |
| SCHEMBL1044081 | 0.81 | GCK (0.55) | GCKKCNH2 | |
| SCHEMBL12811382 | 0.80 | GCK (0.61) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL2667167 | 0.80 | GCK (0.61) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL1426930 | 0.80 | GCK (0.53) | GCKCYP1A2ABCB1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-2272834-A1 | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2272834-A1 | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318968-A1 | Chemical Compounds | GCKR, GCK, HK1 | GCK 2/4885CYP1A2 515/4885ABCB1 1917/4885 |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | GCK, GCKR, HK1 | GCK 1/4885CYP1A2 204/4885ABCB1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.